No Data
Zhifei Biotech: 2024 Semi-Annual Report
Zhifei Biotech: 2024 Semi-Annual Report Summary
The batch issuance of the quadrivalent HPV vaccine has dramatically decreased, and chongqing zhifei biological products' revenue and net profit have both declined. Interpretation of the financial report.
Due to the decrease in sales volume of H1's main products, Chongqing Zhifei Biological Products reported a decrease in revenue and net income in its semi-annual report. The volume of Merck's quadrivalent HPV vaccine, which the company represents, decreased by more than 90% compared to the previous year. With the accelerated development of domestically-produced nine-valent HPV vaccines, the company's pressure will further increase.
Chongqing Zhifei Biological Products (300122.SZ) releases its half-year performance with a net income of 2.234 billion yuan, down 47.55%.
Chongqing Zhifei Biological Products (300122.SZ) released its 2024 interim report, during which the company achieved revenue...
Chongqing Zhifei Biological Products (300122.SZ): The net income in the first half of the year was 2.234 billion yuan, a year-on-year decrease of 47.55%.
Chongqing Zhifei Biological Products (300122.SZ) announced its semi-annual report for 2024, with a total operating revenue of 18.258 billion yuan, a year-on-year decrease of 25.31%; a net income attributable to shareholders of listed companies of 2.234 billion yuan, a year-on-year decrease of 47.55%; a net income attributable to shareholders of listed companies after deducting non-recurring gains and losses of 2.23 billion yuan, a year-on-year decrease of 47.04%; basic earnings per share of 0.9322 yuan.
Express News | Chongqing Zhifei Biological Products Says H1 Net Profit Down 47.6% Y/Y
The Market Doesn't Like What It Sees From Chongqing Zhifei Biological Products Co., Ltd.'s (SZSE:300122) Earnings Yet As Shares Tumble 26%
No Data
